SCHEMBL25322263

SCHEMBL25322263

CC(C)(N)Cc1nc2cc(Br)ccc2s1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 2/20 0.47
DYRK1A Q13627 1/20 0.44
LOXL2 Q9Y4K0 1/20 0.43
TRPV1 Q8NER1 5/20 0.42
NPC1 O15118 2/20 0.40
RAB9A P51151 2/20 0.40
GAA P10253 2/20 0.40
MAPK1 P28482 1/20 0.40
AKR1B1 P15121 2/20 0.39
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
ADORA1 P30542 1/20 0.38
TUBB4A P04350 1/20 0.38
TUBB P07437 1/20 0.38
TUBA3C P0DPH7 1/20 0.38
TUBA1B P68363 1/20 0.38
TUBA4A P68366 1/20 0.38
TUBB4B P68371 1/20 0.38
TUBB3 Q13509 1/20 0.38
TUBB2A Q13885 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25336719 0.91 PPARA (0.41) PPARADYRK1ALOXL2TRPV1NPC1
SCHEMBL25323599 0.84 PPARA (0.44) PPARADYRK1ALOXL2TRPV1NPC1
SCHEMBL25321539 0.82 DYRK1A (0.42) PPARADYRK1ATRPV1RAB9AAKR1B1
SCHEMBL31003151 0.80 NPC1 (0.63) PPARADYRK1ALOXL2TRPV1NPC1
SCHEMBL3247063 0.80 LOXL2 (0.65) PPARADYRK1ALOXL2TRPV1NPC1
SCHEMBL2947099 0.80 NPC1 (0.63) PPARADYRK1ALOXL2TRPV1NPC1
Iodide SCHEMBL31511840 0.79 LOXL2 (0.63) PPARADYRK1ALOXL2TRPV1NPC1
Hydrochloric Acid SCHEMBL29456890 0.79 LOXL2 (0.63) PPARADYRK1ALOXL2TRPV1NPC1
Hydrochloric Acid SCHEMBL20511957 0.79 LOXL2 (0.63) PPARADYRK1ALOXL2TRPV1NPC1
SCHEMBL25324587 0.78 PPARA (0.51) PPARADYRK1ATRPV1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250171432-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2025-05-29 US disclosed
US-20250163048-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2025-05-22 US disclosed
EP-4469447-A1 COMPOUNDS AND METHODS OF USE Tango Therapeutics, Inc. (US) 2024-12-04 EP disclosed
EP-4469455-A1 COMPOUNDS AND METHODS OF USE Tango Therapeutics, Inc. (US) 2024-12-04 EP disclosed
WO-2023146990-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. (US) 2023-08-03 WO disclosed
WO-2023146990-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. (US) 2023-08-03 WO disclosed
WO-2023146989-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. (US) 2023-08-03 WO disclosed
WO-2023146989-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. (US) 2023-08-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250171432-A1 COMPOUNDS AND METHODS OF USE ABCG2, F12, CYP2C9 PPARA 3561/4885DYRK1A 4528/4885LOXL2 3879/4885
US-20250163048-A1 COMPOUNDS AND METHODS OF USE RB1, CYP1B1, REN PPARA 3701/4885DYRK1A 3578/4885LOXL2 3586/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.